Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Carasent, Audiocast, Q1'25

By Inderes4/11/2025, 6:00 AM
Carasent

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Daniel Öhman
00:01 - 14:57

Good morning and welcome to our presentation of the first quarter of 2025. My name is Daniel Öhman and I will start the presentation, and then I will hand over to Svein Martin Bjørnstad, our CFO, to continue with the rest of the presentation. Um, so looking at the first quarter, we continued to improve rapidly. Uh, we have our EBITDA margin going from -8% to +6%. And that's our most important financial metric internally. Um, and performance is in line with our plan. Uh, overall, we have slightly higher costs in the quarter than we had planned for. And it’s not a lot. We're talking about 1 to 2 million more costs than we would have liked to have. So it's not a big deviation. And this deviation is partly due to our decision to invest more into AI. And then we're talking about AI in our products. In our development, we've been working with AI for a long time, and we've been able to offset most of the costs of development by reducing other expenses. However, a portion of it has contributed to an increase in our total costs. We also had to do some write-down of the receivables from the companies that went bankrupt, which we spoke about in the last quarter. We have also had discussions with the board about capital allocation, and I will get back to that later in the presentation. And I feel that we have made good progress in our large development projects, particularly in surgery for Sweden. E-prescription. There's a new regulation around E-prescription called NLL in Sweden, which means that in all EHR systems, you will be able to see all prescriptions from all other systems, and you will also be able to change those prescriptions. So there will be a really good thing for our customers that even if you're not in one of the regional systems, you will still be able to see everything around medication and that way around also. Volvat is proceeding according to plan. The implementation of the method in Norway. Um, we're also building our patient platforms for Norway. That's going well. And Webdoc X continues to develop for the German market with a lot of new functionality. So in total, I think that we see really good progress in our development projects. Nowadays, the bankruptcy is for some customers. Uh, regarding the one we spoke about in the last quarter, there are no major new ones. However, there is a bit higher pressure on sales now. Uh, we are selling better and better every quarter. We are getting a bit better at selling. So I think that's really good. And we can follow that. Uh, we're learning. We do new things in marketing. We see that we can do different things and that our reputation is getting stronger and stronger, which makes it easier to sell. Uh, yeah. So that's really positive. And we need that, uh, because of those, uh, bankruptcies and sign-off error is now at 12 million. So, that's slightly down. And that's because we have implemented a metric for the year. So that's why, and we have not signed any new major contracts. Um, and we have 14% organic revenue growth and 26% growth in the contract area. So, uh, as we started to talk a little bit about AI in our products, I just want to take the opportunity to talk a little bit about what we're doing and how we're thinking about it. So, yes, briefly, there are basically two types of AI support in our products that we could do. One is clinical decision support. So that's when we help doctors, nurses, and physiotherapists make decisions about what to do with the patients. So that could be an automatic triage, where AI determines the severity of the patient's problem and automatically guides them to the appropriate level of care. We never aim to build this type of decision support ourselves. That's because this type of AI solution or solutions in general don't have to be. AI places you in a very challenging legal framework called the Medical Device Regulation (MDR), and you essentially become a research company, requiring you to demonstrate in extensive studies that your actions are consistent and your advice is correct, and so on. So that will never be our aim to build those types of solutions, either with or without AI. It's also not a big topic for our customers. We sell mostly to the private sector, and the private sector handles patients with less complex needs. That's what they're there for. So the clinical decisions are not what takes a lot of time for our customers. The other type of support is administrative support, and this is what our customers really dislike as it takes up a lot of their time. All the reporting to different places. For example, we already do a lot with it. One of our strengths is that our systems are very user-friendly, easy to use, and have good workflows. We also have a lot of automatic reporting connections between systems. So, using our products, you have to do much less administration than in many other systems. But still, there are things we can do. And what we are investing in at the moment is what's called ambient listening. So that means the AI listens during the patient meeting and then automatically proposes a medical record for you. We've been experimenting with it for quite some time. I think we've been playing with it for about two years, and actually, last quarter we felt that it's now time to start really putting it into our products. We don't really feel that we have to be the first mover, nor the opposite. In fact. We want to see first that the use cases are there, that customers really appreciate new technologies and new solutions, and having this strong EHR position where we are the dominant provider of a system to our customers and a difficult to change system. We are in. We don't have to be the first mover. It's easy to just replace whatever they're using or at least adapt it. Our advantage in these types of scenarios is that we can build it directly into the system. So we get really tight integrations, and we have access to all types of data around the patients and visits, and whatever it is within the clinic. So that means that we can build support that utilizes all that knowledge. And that's why I think that sometimes it's right for us to do it, but not always. And that's what I want to show you on this next picture. So, um, different situations and different customers have different needs and we will not try to solve all by ourselves. Here are some examples when we talk about ambient listening, which we're selling now or starting to sell now. But what they lack is knowledge about how an EHR, or medical note, is supposed to be written in Sweden, how we set diagnoses, and so on. So they are good at certain things, but less good at other things. We sell their products today, and they're really good at, for example, speech to text where the doctor just talks and it writes exactly what the doctor or nurse says. Their ambient listening is not as well suited for such circumstances at this point in time. There are also specialized products. Another example is Denny's Tandem, which many of our customers also appreciate. It's built for our type of customers. Uh, their niche. So they can really focus on this. Uh, and they can really invest in it in another way than we do and take higher risks than we would with this type of solutions. And they will be right for a certain type of customers. For example, they built an app so that you can take the listening experience with you when you leave your outpatient office. So if you're a physiotherapist and you go out to the training floor, you can take that with you and record the entire meeting. It might not make sense for us to build such an app, for example, because it's maybe 10% of our use cases for our customers. And then we can have our own integrated system. And the advantage we have is that we can build really seamless workflows as we do with other things. So it's always the right patient. You start it all within the same system. You don't have to switch windows. You don't have to go into other things. You don't have to copy things. We also build for our type of customers, and we have access to all the data that could be needed to write a really good medical record. But I think all three of them probably have their place. And it's also difficult to foresee exactly where technology will take us and what will happen. So we do not put everything on one horse or whatever you call it. So we're doing all these three things. But we think that for many customers, our solutions are probably the best choice. And we aim to ensure that it is. That's a bit about how we're thinking about AI in our products. And over time, we see that we will add more and more administrative support in our systems. And that's why it's important to start releasing those types of features in our systems. Also worth mentioning is that the feature we're releasing now is applicable to all our systems. So it's already included in Webdoc X in pilots, and also in Webdoc X for Germany. It will soon be in our Norwegian systems and it's all using the same backend, but it's being trained on different languages, so it has a slightly different backend, but within the same organization that builds it. Moving on, we talked about how we use our capital and looking at how we grow. And new sales are, of course, very important. It's worth noting that most of the new sales are to startups. So clinics start anew, and then we grow with them. So new sales are extremely important. More important than it looks like in the numbers, because it's with those new startups that we then grow in the coming years. New sales are very important, even if they are often small. With surgery, we aim to also expand into larger clinics and increase that aspect of our new initiatives. We grow with existing customers. As mentioned, that's due both to their growth and to the increasing value we add to our systems, including different add-ons we can sell, and then we have acquisitions. And what's really important to note here is that we do not aim to make acquisitions by looking at various structured processes originating from advisors and so on. We have a few companies that we know would add a lot of value to our organization and that we would, over time, like to acquire. So what this means is that we would go and knock on the door and say hi. We think that we could add value by creating more value together and then have a discussion. So that's very different from the acquisitions of old in this company. But it's the same strategy we had in Germany, where we looked at all different providers. We knocked on a few doors and said, hey, we think that together we would be a good fit. And that's how I've done acquisitions before as well. I think that's where you can really create a lot of value, having chosen this and that company slash product that fits really, really well with our company. So we're not aiming at becoming a serial acquirer or so, but we see that there are some opportunities to create real value and strong positions. So that's what we're talking about. There will not be many acquisitions, and they won't be in a rapid pace. Um, regarding our capital allocation, we see that we want to do some acquisitions, but they are very targeted. Um, and we also have 253 million SEK on hand already. Uh, and we have a rapidly increasing cash flow. So that means that we will do recurring share buybacks. The exact size of those will depend on the discussions we have with those M&A targets I spoke about earlier. So the board will decide on how much to buy back when they think it's the right time to do it. Uh, so, uh, I hope that we, uh, quite soon after the AGM will be able to come back to you all on that and what size it is this year. Um, but I cannot give you that answer today. Um, but we see that share buybacks are a good way of distributing cash to our shareholders. And then we will be looking at a few very selective M&A opportunities. And looking ahead, we continue to have a big focus on growth, of course, and we have pilots in three very high potential projects ongoing at the moment. So with surgery, our Volvat's very first pilots are live now and also MedSum, which is our ambient listening solution. We also have pilots live. So three very high potential projects that will be really fun to follow. Uh, we continue to focus on the efficient use of resources every day, every month, every quarter, becoming more and more efficient in all parts of what we do. And I think that's extremely important. That's how we'll be able to scale in a really good way. And cost control is vital. Um, and finally, launching Webdoc X in Germany. And then we also have our largest high potential project. So the fourth one, with the first German pilots active, as you know, and we aim to replace Datacure, the older product, with Data-AL during 2025. So with those words, I will hand over to Svein Martin.

Svein Martin Bjørnstad
14:58 - 22:53

Uh, we continue to focus on efficient use of resources every day, every month, every quarter, becoming more and more efficient in all parts of what we do. Um, starting off by looking at high-level metrics. Uh, we improved a lot. Also in Q1, our ARR grew 26% to 321 million, including the backlog, and our organic recurring growth was more or less in line with previous quarters. Net retention rate was also at 110%. And then margins also improved. Uh, we did expect the margins to improve a couple of percentage points more, but, um, we had this, um, additional cost, um, that was mentioned. Um, but overall, uh, the quarter was in line with our plan. If we take a closer look at the P&L, you see strong improvements year-over-year; revenue growth was 29%. Um, and, uh, we have highlighted some points here where Webdoc grew at 15%. So there you see that it's slightly lower than what we posted last year. And this is because these bankruptcies, or churn, took full effect from the end of Q1. So, going into Q2 as well, the pace will be affected by this churn. On the other hand, we did have a very strong quarter on the sales side in Webdoc in Q1. So, uh, we expect them to be back on track quite, uh, quite fast. Uh, overall growth, as mentioned, was 29%, driven by the acquisition of Data-AL and strong organic growth. Consulting revenues were also very high. Um, this was due to these big implementation projects being at full speed and also, uh, sort of weak comparables. Last year, it was quite slow on consulting. Uh, it is worth noting as well that in the first quarter, we were close to being neutral on EBITDA for our German operations. And this was because of a very strong quarter on the profitability side for Data-AL, which had good consulting revenues, which helps, of course. And also, we have gone through the cost base after acquisition and removed unnecessary costs, particularly on the OpEx and COGS side, and also negotiated with suppliers. So the underlying profitability now is better than before the acquisition. Uh, if we look into the growth, um, our growth was, as mentioned, uh, more or less in line with previous quarters in the reported figures. Uh, but there are some effects that pull in opposite directions. So, um, as Daniel mentioned, we implemented a VGR contract for Madre and also established some clinics for men in Norway, which contributed to the growth that would have increased by a couple of percentage points, but then the Webdoc exit due to bankruptcies took full effect in these figures. So that pulled in the other direction. So overall, it was quite stable. Um. If we look at the profitability, it's improving rapidly. And we have gone from a -30% margin two years ago to a positive 6% now. We are, of course, still far away from our potential. Uh, and the key, given that we have a strong backlog of revenue to implement and a good underlying growth momentum, will be to convert as much as possible of those revenues into profits. Um, if we look at this slide, it shows how we are doing with this over the last year. So the left-hand bar shows the revenue growth and the revenue increase, excluding Confrere, which was sold, and Data-AL, which was acquired over the last year. So, in the organic business, the COGS naturally increased. Um, opex was quite flat. Uh, and then the personnel expense increased by 2.6 million. Uh, but last year, we did have some one-offs related to layoffs amounting to 1.7. So if we remove those from the comparison figures, it increased 4.3. And then CapEx decreased by a similar amount. So in total, we were able to convert 90% of the revenue increase into EBITDAC. And if we adjust for the non-recurring items last year, it was 73%. So I set an internal target to convert around 80%. Um, and um, yeah, we did have this extra cost this quarter. Next quarter, we will incur around a million in extra costs for the new incentive program. So it will be key that we succeed in these cost initiatives that we are undertaking. Uh, and over the last year, we have removed roles that were not necessary and also replaced the consultants with employees, which typically generates good savings. So that is why we are able to keep these costs quite flat, even though, of course, we have wage increases, etc. and add roles in other areas. Um, finally, the cash flow, we had, as mentioned, good improvements in profitability and lower investments. Um, but we had the working capital headwinds. So I mentioned this in the last report that we had a lot of outstanding invoices for the relisting at the year-end, and these were paid in Q1. This had an impact of around 12 to 13 million. So if you look at the figures, it would have been quite strong if we hadn't had this effect on the cash flow. So overall, financially, we developed according to plan and in line with our financial targets for the year, despite some smaller items on the cost side. So um, with that we can open up for Q&A.

Operator
22:56 - 23:15

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Frederik Nielsen from Redeye. Please go ahead.

Fredrik Nielsen
23:18 - 23:41

So I mentioned this in the last report that we had a lot of outstanding invoices for the Relisting at the year end, and these were paid in Q1. Good morning, Daniel and Svein. Martin. Um, I want to start with the new AI functionality. Could you perhaps elaborate a bit on what share of customers you believe will be interested in your solution relative to third-party solutions. And also, if you could say something about the pricing.

Daniel Öhman
23:42 - 28:46

Yeah, sure. Um, thanks, Eric, and good morning. Um, so I believe that over time, we will be able to sell to a really large portion of our customers. These types of solutions. Um, it has the potential to, to. I mean, what doctors do when they have an outpatient day, or physiotherapists or nurses, for that matter, is that they see the patients, but then they have a lot of documentation to do afterwards. If we can automate more for them, they can really help more patients. So it's really a big potential in time-saving for the user. Um, of course, none of the AI solutions today, I mean, deliver 100% of that time saving, but they're doing a really good job. And, therefore, over time, I think that we will see a really large part of our customers using these types of solutions. Um, I think that also, um, our solution will have clear advantages, uh, by being completely connected into the system and just being a part of it. It's a natural part of the EHR system. It's not a system on the side, but you have to pay to get access to it. And then it opens up, and you have access to it in the system or in our systems, so to speak. So I think the potential is really strong. Um, and then healthcare is always slow to take on new technology. So I think it will take some time before it grows really big. But the reason why we have chosen to kind of overinvest compared to the plan is that I believe the potential is really strong and the pricing from our side will be very competitive. So, we build our solution based on open-source products. So that means that our costs will be quite low. And then we are hosting it with our own infrastructure, so to speak, just like we do with our other systems. Uh, so that means that we can scale costs in a very good way compared to if we would use ChatGPT or similar solutions. Uh, we can also make sure that there is no access from the US to our solutions, which we cannot guarantee 100% if you're on an Azure cloud. So I think that we have some clear advantages, and the pricing will also be lower than the competition. In general, these types of solutions sold today are a bit more expensive than the licenses for EHR systems per month. So yeah, we will be a bit pricey, a bit lower than what the EHR license is. But yes, in Webdoc, I think we have 18,000 users. Our estimate is that more than half of those generate medical notes. So the potential is really strong. And I mean over time, that could really be an area for growth. So that's why we've taken this choice to overinvest a bit. But most of the costs we've been able to offset by having to outcompete other projects. And we have removed some roles we maybe hadn't planned to remove before. So, so I think that's been a priority for us. And that wants to. Yeah. There's really big potential in these types of solutions. I think over time we will see more and more built-in AI support, just like we have seen, with more and more integrations. And given the types of customers we sell to, we can be very quick at implementing these types of solutions. If you're selling to the public system, it's completely different because they have to go through the tender process and all the committees, and we can be a couple of years before that easily. So I think it's also an advantage when comparing different systems. Um, so that was Chair of Uses, you said. Uh, so I think that over time we will be able to sell to, to most. And I think that our solution is likely to become the most popular among our users. But it's hard to tell exactly where these types of technologies will go. Um, so I think it's important not to, you know, put all eggs in the same basket. And we're selling our own and we're selling the other solutions too. So that's, I think it's fine. But of course, our margins are much better when we sell our own solutions. Did that answer your question, Fredrik?

Fredrik Nielsen
28:47 - 29:10

Yeah. Yeah, absolutely. That was a good answer, I think. Um, I want to, I have some questions about the opportunity for Webdoc X outside of the three largest regions in Sweden. Uh, what is the timeline like relative to the three large regions? And what can you do to potentially open up additional regions?

Daniel Öhman
29:11 - 29:13

Well, can you say, what's the timeline? Timeline.

Unknown 1
29:13 - 29:15

Market? Timeline.

Daniel Öhman
29:15 - 29:16

Time. Um, so I think it's important not to, you know, put all eggs in the same basket. Sorry.

Unknown 2
29:16 - 29:17

I mean, look.

Fredrik Nielsen
29:17 - 29:19

Look at it in terms of the long-term timeline.

Daniel Öhman
29:19 - 32:24

Yeah. So, private healthcare is by far the largest in the three biggest regions. And by far it's Stockholm. That's the, uh, just so. So Stockholm is really the big market. So, Stockholm is really the most important market. Uh, then there are private caregivers around the country. We have customers in all regions. Uh, so, uh, where we really are locked out in many regions is primary care. You have a few primary caregivers, like 2 or 3 in a region, then it's really not significant. Or maybe ten. I mean, that's very little and doesn't generate much revenue. But in total, all those regions add up to something substantial. Um, it's not. We're working a bit on it to open it up. Um, so we have a project in one region where they've now rolled out Cambio and the private caregivers are really not happy. Uh, and we have discussions where they can be positive. And I received feedback indicating that the reading is positive, but we might be able to do something, although I think it will not generate a lot of revenue. But I think the point of that project is just to prove it and to show whether it works. Well. I think that over time we will have the new regulation. EDIH or 'Digital Innovation Hubs,' I should probably say, which indicates that all systems have to be able to and must actually exchange information with each other. So I think that for us, it's an excellent opportunity. Then all those arguments go away, because all systems have to be able to talk with each other, and that's by 2020. I think it should be implemented in most areas by 2030. So, there's a lot of work going on with that. Uh, we're sitting in those committees working on those proposals together with other care providers. Um, so that will also open up a lot of markets. But at the moment, we are fully focused on capturing those opportunities. I mean, there are so many caregivers to sell to, and we can grow significantly within existing potential markets that we don't need to focus on other markets. I mean, potentially in BGR, if they go for one of the proposals that have been proposed, they will have a floor of different systems. Then potentially we could sell to the public primary care centers. Um, that's never been a focus for us. And it's not included in our TAM numbers. If that were to be the case, it would open up. But it's not really necessary at this point. We don't need to fight to get those types of new situations where there are so many customers we can sell to already.

Fredrik Nielsen
32:29 - 32:47

Okay, I see. That makes sense. I mean, that's very few and not much revenue. And lastly, just a clarification regarding the churn. As you mentioned in the last quarter, you will see an uptick in churn in the beginning of this year. Is all of that taken in Q1 or should we expect a further increase in Q2?

Svein Martin Bjørnstad
32:48 - 32:58

Uh, so that was um, the full effect of that was in the March figures. So in our ARR, it's, um, it's accounted for.

Fredrik Nielsen
33:01 - 33:03

Great. That's clear. Thank you very much. That's all for me.

Svein Martin Bjørnstad
33:04 - 33:05

Thank you.

Operator
33:08 - 33:13

The next question comes from Elvin Roleder from Carnegie Investment Bank. Please go ahead.

Elvin Roleder
33:17 - 33:59

Uh, good morning, Daniel and Martin. I hope you can hear me. Congratulations on a good report. Solid, solid growth. I have a couple of questions. More nitty-gritty in nature. Um, if I may. Uh, you mentioned that the opex increased partly due to the increased investments into AI, but also that there were some writedowns of receivables for these customers that had gone bankrupt. Uh, would it be possible to clarify, as you said that the AI investments were 1 to 2 million. How much were the write-downs of receivables? So we get a feeling for the size there.

Svein Martin Bjørnstad
34:01 - 34:13

Uh, so in total, the extra costs were 1 to 2 million. So nothing dramatic, but slightly higher than we expected. And then the write-off of receivables was, uh, the majority of that.

Elvin Roleder
34:16 - 34:43

Is all of that taken in Q1 or should we expect a further increase in Q2? Uh, and if we think about the AI costs, you mentioned that you were able to offset most of it here in Q1. How should one think about that for the rest of the year? I mean, how much will that drive an increase in opex. If you look at it compared year over year, will you still be able to offset it? Or how should one think about that for the rest of the year?

Daniel Öhman
34:44 - 36:19

Yeah, I know we should be able to continue to offset most of it. Uh, what possibly could happen? Because I think you need to be a bit flexible on these kinds of things, if we see that now we're running pilots, when we start selling, and if we see it really starts selling. Well, I think we might invest more in it. Um, but we have chosen to invest more in it than before. And go a little bit beyond our budget just because we see that there's such great potential in it over time. And then we have kind of made it a little bit more difficult for us to live up to the targets for this year, we think. We still think we can do it, but we've made it a bit more difficult for ourselves to deliver in the short term. But for the long term, we feel strongly that this will create more value. So the choice we have made, we try to offset most of it and we continue to have that offset. It's just, you know, prioritization between different roles and different projects. So, but we have chosen not to offset it completely because we strongly believe in many of the projects we had planned to run. And then this is starting to really show some great potential. And I think it's also important because I believe this will be one of the technologies that will be used in our products. And then I think it's very important that we also start learning how to commercialize those types of technologies, but most of it will be offset and it will not be a major factor.

Elvin Roleder
36:22 - 36:50

Yeah, I know we should be able to continue to offset most of it. Yeah, I know we should be able to continue to offset most of it. Uh, and, uh, a bit related to the AI investments then. Are there any hardware adaptations or anything you need to do on that front? I know that some of these, like AI assistants and so on, use specific hardware that is adapted to that assistant or something. Is there anything you can do there, or is it just plug and play? You need just an ordinary mic. It's a bit of a weird question, but, uh.

Daniel Öhman
36:51 - 36:53

No, no, but that's, uh, that's that.

Elvin Roleder
36:53 - 36:54

What you need to do.

Daniel Öhman
36:54 - 38:20

Yeah, I know we should be able to continue to offset most of it. That's some good guidance. Yeah, those are some good points to make there. So we're not running our own data centers. I think that's important. We do set them up ourselves. These are private clouds. So I think that's important for our customers and the type of data we handle. Um, and, uh, we're the ones configuring all of it, but it's not our hardware. And with AI, we use much more hardware than we do for our normal solutions. So that means that for these types of solutions, the cost is higher than what we used to have. So they will be around 25 to 30% somewhere around there, I think. Um, it's difficult to foresee. Exactly. We're experimenting with smaller models as well. And if you train them, they can be really good, allowing you to reduce those costs significantly quite a lot. But at the moment, our focus is not to reduce them the most; it is to ensure really good quality in the outcomes. And then after that, we can try to go to smaller models, and in that way, have a better margin. But first, we want to win customers. So, I think we will not buy any hardware, but we will have COGS of 25 to 30% on those products to start with, at least. And that's just all the data, yeah.

Elvin Roleder
38:22 - 38:46

We do set them up, uh, ourselves. Okay, cool. Um, and then a bit on Germany, I guess. Uh, can you comment a little bit on the initial feedback you have gotten there with Webdoc X. Uh, and how should one, I mean, how should one think? And when you're ready to, like, fully, fully sell the first version of Webdoc X for, like, actual use and so on. How's the time there?

Daniel Öhman
38:47 - 40:58

Yeah. So, um, the first pilots seem happy, but those pilots, when we talk about the AI projects, are called MedSum. And when we talk about surgery, those are full-scale pilots. Uh, so they're using the systems every day, all the time and in all circumstances. Webdoc X does not have the full functionality to be used and completely replace your existing systems. So that's a big difference from other types of pilots we have, where they have completely moved away from other types of solutions. And they use it full-time, all the time, every day. So these are users testing functionality for us. But then they also have to use the normal system. And that's because, for example, billing cannot yet be done in our system in Germany. Um, so we really know exactly what to build. The Data-AL organization is really good at making sure that we build exactly what the customers need. And, uh, there is a clear roadmap. And during this year, our aim is to replace all of the users who currently use the existing data products with our new product. And that means that by the end of the year, we should have around 80 paying customers, I think, in Webdoc X Germany. And that's, I mean, that's quite okay. It's, uh, then in physiotherapy, so they pay a little bit less than doctors. And in general, clinics in Germany are a little bit smaller than in Sweden. So, uh, if you look at Webdoc X Sweden, we have 800 customers, a bit more. Um, but the average size is much bigger than those first 80 German clinics. But from there on, we can continue, of course. And then we're moving to doctors the year after. So. So that's the timeline we're working towards and aiming for.

Elvin Roleder
41:02 - 41:12

So these are the users testing the functionality for us. Perfect. Uh, I think that was all from my end. I'll, uh, get back in line to see if there are other questions. Thank you so much, guys. Have a good day.

Daniel Öhman
41:12 - 41:13

Thank you.

Unknown 1
41:13 - 41:13

Thank you.

Operator
41:15 - 41:23

Because there are no more questions at this time. So I hand the conference back to the speakers for any written questions.

Svein Martin Bjørnstad
41:24 - 41:38

Okay, we have gotten quite a few questions in the chat here. Um, first one's from Jasper. Are you able to charge extra for the AI transcription feature that you're launching?

Daniel Öhman
41:38 - 41:48

Yes, definitely. So the cost for that will be roughly 70 to 80% of the license cost, somewhere around there.

Unknown 1
41:48 - 41:48

Mhm.

Svein Martin Bjørnstad
41:50 - 42:00

Um, next one, you mentioned strong new sales in Webdoc X. What has improved from before? Is it sales efforts or an improved product?

Daniel Öhman
42:00 - 43:13

I think it's very difficult to break. It's difficult to separate those two aspects. Um, the product is improving, I think. Um, it will and it will be improving more and more all the time because we become quicker and quicker in our development. And so that really helps. But I think also it's within sales and marketing that we're learning and improving all the time. And I think I mentioned before that add-on sales were something we were not very good at initially, and it took a bit longer than we had hoped to get started. But after the summer last year, we really started to make progress on that, and it has continued to improve. And for all months so far this year, we're selling both to new customers and add-ons at a higher pace than planned. So, and the plan was slightly elevated from last autumn. So, uh, and in our plans, uh, we have, uh, increasing sales all the time. So we get better and better and better at it. So that's a little bit of the everyday improvement I've been talking about.

Svein Martin Bjørnstad
43:13 - 43:39

But okay. Next question is from Rasmus Persson. Um. First one, uh, can you give us more information on the operations? Um, module, how many trials do you have? And have you closed any deals yet? Are there any discussions with large customers? And what do you expect from it by the end of the year?

Daniel Öhman
43:39 - 45:51

Yes. So, um, um, we have one pilot using a certain module fully, and they are really pleased with the functionality. They are all happy. Um, as I remember the contract, they will start paying in half a year, or maybe in four months or something like that. Um, we're getting the second pilot up and running, uh, any day now, and it could already be up and running. I'm not really sure. And they will also become paying customers after a couple of months. Month. We have a third one going online quite soon. Who will be paying customers? But all of these are existing customers that have been lacking this functionality. So it for sure adds some revenue for us. Um. So that's good. But the real aim of this module is to add new customers, large new ones, and we are in those discussions. It takes time to convince if you have a small hospital of a couple of hundred or 100 users, as they are not the quickest to change, and they want to see that everything is top-notch in all parts of it before they change systems. Um, and I can understand them, as the previous customers have been promised a lot by software companies, and then they don't really deliver what they've said on time. Uh, so they want to see everything in place, all parts, and reports before committing, and I can understand that. So I think that, uh, month after month, we should really see good development with new customers, and it will help us add new customer sales. Um, but it will not be, uh, like, uh, going from 1 to 200 in a couple of months; it will be customer by customer. But we have a new, effective tool to engage large customers, giving us a significant advantage over the competitors. So I think that, step by step, you will see sales increasing. And partly thanks to the surgeon module.

Svein Martin Bjørnstad
45:53 - 46:00

Um, and I, as I remember the contract, they will start paying in half a year or now, I guess, four months or something like this or four months. Next one, uh, if you can give an update on your customers' actions against Vgr and Millennium.

Unknown 1
46:01 - 46:01

Yes.

Daniel Öhman
46:01 - 47:18

Uh, so um, then, uh, was judged against our customers. Um, we believe that it was very fair. Judgment. Uh, of course, we think so. But it's also. I think that anyone would think so because the reasoning they used was that it was not proven that it was much less work or less, uh, what's the right word? Um, they said it was not proven that it would be much easier for our customers to live with our existing system than changing to Millennium, and that was not something that we tried to say. It wasn't the case. So it was not part of what was actually discussed. So they just ruled on something that was not discussed and not part of what shouldn't be included in the ruling. It should only be things that the parties are not agreeing on that should be ruled on. So, uh, typically in these cases, when you are in this type of course, only around 12 to 14% actually get through when you try to appeal.

Unknown 1
47:19 - 47:20

Appeal.

Daniel Öhman
47:20 - 48:09

Appeal. Thanks. Uh, when you try to appeal, that case actually gets to go to an appeal court. So it's not like normal courts. Um, we believe that our customers have a good case for getting their appeal through. They have appealed, and we think they should be able to get the ruling in an appeal court. But it's not a given that, since normally only 40% of all appeals go to the next level. Um, that being said, I think that Millennium is a bit difficult to see how Millennium could go forward in its present form. And we have good discussions with primary care centres in the region about switching to Webdoc X now. So we'll see. But I have my fingers crossed, and we will have some new primary care customers in Webdoc X within. Not too long.

Svein Martin Bjørnstad
48:13 - 49:44

Great. Next one is on quantification of the receivable loss. I think we addressed that. And then the question for me is whether the 80% revenue to profit target is for 2025 or long term. Um, so that is an internal goal that we have set. And it's basically reflective that we are at a level on the margin side that we think, as I said, we are far from our potential margins. So, we think we can grow for quite some time without significantly increasing the cost base. So, so that's sort of the internal target. Then from yes, that's also on the VGR appeal. So I think we can skip that. And then the final question we have gotten is also related to this 80% incremental EBITDAC, implying that basically all additional gross profit translates into EBITDAC. Is that correctly understood? Our gross profit is around 85%. So it basically allows us to add some roles where we see the need. But, uh, yeah. Not a lot of wiggle room there. And I think that's important as well. If we are, if we should deliver on the plan, we have to increase margins rapidly.

Unknown 1
49:46 - 49:47

Yeah.

Daniel Öhman
49:47 - 50:07

And also to mention the last part, we have the capacity when it comes to development. And we become more efficient in all roles. So I think that's what it builds on. And those were all the questions we had for today. So thank you all for listening in and just, you know, reach out if you have any further questions. Thanks for this morning.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…